IQCG Inhibitors
IQ domain-containing protein G (IQCG) inhibitors are a diverse set of chemical compounds that interfere with various signaling pathways, leading to a decrease in the protein's functional activity. For instance, staurosporine and chelerythrine, as potent protein kinase inhibitors, can suppress the phosphorylation of IQCG or its associated proteins, thus diminishing its role in signal transduction. Similarly, calyculin A inhibits PP1 and PP2A, leading to altered phosphorylation states that can negatively impact IQCG function. PKC inhibitors such as Gö 6976 and GF 109203X further reduce IQCG activity by affecting phosphorylation levels in pathways where IQCG is involved. LY 294002 and wortmannin, both inhibitors of PI3K, disrupt IQCG-mediated functions by impeding PI3K-dependent signaling.
Additionally, compoundslike U0126 and PD 98059 target the MAPK/ERK pathway, with U0126 specifically inhibiting MEK1/2 and PD 98059 selectively targeting MEK. This results in a decrease in ERK signaling, which in turn can lead to diminished IQCG activity if it is involved in this pathway. Rapamycin, through its inhibition of the mTOR pathway, can also lead to decreased IQCG function by affecting mTOR-regulated processes that may involve IQCG. SB 203580 and SP600125 target other members of the MAPK family, namely p38 MAP kinase and JNK, respectively. The inhibition of these kinases by SB 203580 and SP600125 can lead to reduced activity of IQCG if it is associated with stress response or inflammatory pathways regulated by p38 and JNK. Collectively, these inhibitors operate through distinct mechanisms to decrease the functional activity of IQCG by altering the phosphorylation dynamics and signaling cascades within which IQCG normally operates.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can indirectly inhibit the function of IQCG by inhibiting protein kinases that phosphorylate IQCG or its associated proteins, leading to decreased IQCG-mediated signal transduction. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A inhibits protein phosphatases 1 (PP1) and 2A (PP2A), which can lead to an increase in phosphorylation levels of various proteins. Since IQCG is involved in signal transduction pathways that are regulated by phosphorylation, the inhibition of these phosphatases can result in diminished IQCG activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 is a selective inhibitor of protein kinase C (PKC) isoforms. By inhibiting PKC, which may phosphorylate substrates involved in the same pathways as IQCG, Gö 6976 can diminish the functional activity of IQCG through altered phosphorylation dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). As PI3K signaling is crucial for a variety of cellular processes, the inhibition by LY 294002 can lead to a reduction in IQCG-mediated functions that depend on PI3K activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K can lead to diminished IQCG function by interrupting PI3K-dependent signaling pathways in which IQCG is involved. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of the MAPK/ERK pathway, specifically inhibiting MEK1/2. By disrupting this pathway, U0126 can decrease the functional activity of IQCG if it is involved in downstream signaling of MAPK/ERK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits the mammalian target of rapamycin (mTOR) pathway. Since mTOR signaling can regulate various cellular functions, the inhibition by rapamycin can lead to decreased activity of IQCG if it participates in mTOR-regulated processes. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is a selective inhibitor of PKC. By inhibiting PKC, chelerythrine can lead to a reduction in IQCG activity by altering phosphorylation status of proteins in pathways where IQCG is active. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB 203580 is an inhibitor of p38 MAP kinase, which is involved in response to stress and inflammatory cytokines. Inhibition of p38 by SB 203580 can reduce the activity of IQCG if it is associated with p38 MAPK regulated pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD 98059 can decrease the functional activity of IQCG by diminishing the ERK signaling cascade that may involve IQCG. | ||||||